Author

Yong Chen

Observed name: Y Chen

Institution: Pfizer (United States)

Observed institution: Pfizer (United States)

OpenAlex ID: A5086912837

Long‐lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP‐ribose) polymerase

2011 · F Moroni, A Cozzi, et al. · British Journal of Pharmacology · 54

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

2012 · L P Martin, M F Kozloff, et al. · British Journal of Cancer · 24

Clinical Trial Simulations From a Model‐Based Meta‐Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

2016 · ML Zierhut, Y Chen, et al. · CPT Pharmacometrics & Systems Pharmacology · 12

Evaluating the impact of a statewide intervention on multiple myeloma bispecific T-cell engaging antibody (BsAb) therapy uptake in Florida (FL).

2026 · Maen A. Hussein, Chai Kim, et al. · Journal of Clinical Oncology

Real-world safety of elranatamab in low-weight patients: Findings from the SUMMIT study.

2026 · Satoshi Yoshihara, Aster Meche, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 90

H-index: 3

I10-index: 3